We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.61B
AUM Growth
-$1.09B
Cap. Flow
-$352M
Cap. Flow %
-4.08%
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30

Top Buys

Rank Stock Value
1
OM icon
Outset Medical
OM
+$58.4M
2
BSX icon
Boston Scientific
BSX
+$41.2M
3
PACB icon
Pacific Biosciences
PACB
+$38.3M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$37.2M
5
CDNA icon
CareDx
CDNA
+$32.9M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$109M
2
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$75.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$73.9M
4
DHR icon
Danaher
DHR
+$66.3M
5
HUM icon
Humana
HUM
+$65.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Industrials 0.69%
3 Energy 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$123B
$386M 4.49%
1,480,253
-311,508
-17% -$73.9M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$367M 4.27%
9,918,073
-437,050
-4% -$14.3M
ARGX icon
3
argenx
ARGX
$53.8B
$301M 3.49%
953,238
-43,800
-4% -$12.7M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$283M 3.29%
3,023,451
-157,100
-5% -$13.3M
MRNA icon
5
Moderna
MRNA
$24.5B
$282M 3.28%
1,639,349
-69,900
-4% -$11.8M
INCY icon
6
Incyte
INCY
$23.4B
$226M 2.63%
2,847,400
-109,600
-4% -$7.97M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$210M 2.44%
3,429,619
-199,300
-5% -$10.4M
ELV icon
8
Elevance Health
ELV
$80.9B
$202M 2.35%
411,637
-43,657
-10% -$20M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$201M 2.33%
1,229,563
-105,577
-8% -$16.1M
ABT icon
10
Abbott
ABT
$175B
$192M 2.23%
1,622,927
-122,874
-7% -$15.2M
ISRG icon
11
Intuitive Surgical
ISRG
$122B
$187M 2.17%
620,068
+35,605
+6% +$10.4M
BSX icon
12
Boston Scientific
BSX
$65.4B
$173M 2.01%
3,913,947
+949,916
+32% +$41.2M
UNH icon
13
UnitedHealth
UNH
$387B
$156M 1.81%
305,701
-6,580
-2% -$3.17M
ARVN icon
14
Arvinas
ARVN
$517M
$147M 1.7%
2,179,253
-54,150
-2% -$3.69M
FATE icon
15
Fate Therapeutics
FATE
$324M
$139M 1.61%
3,576,486
-199,250
-5% -$7.72M
TNDM icon
16
Tandem Diabetes Care
TNDM
$1.17B
$130M 1.51%
1,116,508
+167,251
+18% +$19.5M
AXNX
17
DELISTED
Axonics, Inc. Common Stock
AXNX
$128M 1.49%
2,049,205
+177,191
+9% +$9.55M
AGIO icon
18
Agios Pharmaceuticals
AGIO
$2.36B
$120M 1.4%
4,129,292
-220,000
-5% -$6.72M
DXCM icon
19
DexCom
DXCM
$29.6B
$120M 1.4%
939,600
-1,012
-0.1% -$111K
SYK icon
20
Stryker
SYK
$123B
$118M 1.37%
440,225
+18,341
+4% +$4.75M
JAZZ icon
21
Jazz Pharmaceuticals
JAZZ
$15.5B
$118M 1.36%
754,981
-131,873
-15% -$19.1M
RLAY icon
22
Relay Therapeutics
RLAY
$4.34B
$117M 1.36%
3,918,962
-187,000
-5% -$4.54M
EW icon
23
Edwards Lifesciences
EW
$49.4B
$107M 1.25%
912,785
-8,400
-0.9% -$942K
PODD icon
24
Insulet
PODD
$11.4B
$106M 1.23%
398,189
+15,466
+4% +$3.8M
BDX icon
25
Becton Dickinson
BDX
$43.6B
$105M 1.22%
406,315
-60,482
-13% -$15.6M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2022 Portfolio in Review

As of Q1 2022, Bellevue Group held 207 positions worth $8.61B, down 11% from $9.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group withdrew a net $352M in Q1 2022, closing 30 positions and reducing 80 holdings. Its most notable exit was VOCERA COMMUNICATIONS, INC., an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Aurinia Pharmaceuticals worth $29.8M.

  • Bellevue Group's largest Q1 2022 buy was Aurinia Pharmaceuticals: 2,405,825 shares worth $29.8M.
  • Bellevue Group added most to Outset Medical in Q1 2022, an estimated $58.4M increase.
  • Bellevue Group's biggest Q1 2022 reduction was Biogen, cutting an estimated $109M.
  • Bellevue Group fully exited VOCERA COMMUNICATIONS, INC. in Q1 2022, selling an estimated $75.3M.
  • Bellevue Group's ten largest holdings make up 31% of its $8.61B portfolio in Q1 2022.
  • Bellevue Group opened 16 new positions and closed 30 in Q1 2022.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $8.61B.

Based on Bellevue Group's 13F filing for Q1 2022, filed 13 May 2022.